Affiliation:
1. Institute of Microbiology, Medical School, University of Genoa, Italy.
Abstract
The antibacterial activity of LY146032 alone and in combination with other drugs was assayed against gram-positive isolates. Synergism was found when LY146032 was combined with netilmicin, amikacin, imipenem, and fosfomycin by both checkerboard and time-kill tests. Indifference predominated when LY146032 was combined with teicoplanin, vancomycin, and rifampin. Under no circumstances and with no combinations was an antagonistic effect detected.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference10 articles.
1. Lack of in vivo and in vitro bactericidal activity of N-formimidoyl thienamycin against enterococci;Auckenthaler R.;Antimicrob. Agents Chemother.,1982
2. In vitro activity of imipenem against enterococci and staphylococci and evidence for high rates of synergism with teicoplanin, fosfomycin, and rifampin;Debbia E.;Antimicrob. Agents Chemother.,1986
3. Antibiotic synergism and antimicrobial combinations in clinical infections;Eliopoulos G. M.;Rev. Infect. Dis.,1982
4. In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic;Eliopoulos G. M.;Antimicrob. Agents Chemother.,1986
5. In vitro activity of LY146032 against staphylococci, streptococci, and enterococci;Fass R. J.;Antimicrob. Agents Chemother.,1986
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献